The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Renal Diseases Drug Market Research Report 2025
Synopsis
Kidney disease commonly referred to as kidney disease or kidney disease, mainly manifested as abnormal urine volume, urination abnormalities, lumbago.Kidney disease drugs include blood pressure drugs, anti-hyperlipidemia drugs, erythropoietics (ESA), diuretics and so on.
The global Renal Diseases Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Renal Diseases Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Renal Diseases Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Renal Diseases Drug in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Renal Diseases Drug include Pfizer, Amgen, Roche, GlaxoSmithKline (GSK), Allergan, AbbVie, Kissei Pharmaceutical, AstraZeneca and FibroGen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Renal Diseases Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Renal Diseases Drug.
Report Scope
The Renal Diseases Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Renal Diseases Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Renal Diseases Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Amgen
Roche
GlaxoSmithKline (GSK)
Allergan
AbbVie
Kissei Pharmaceutical
AstraZeneca
FibroGen
Sanofi
Teva Pharmaceutical Industries
Johnson & Johnson
Keryx Biopharmaceuticals
Segment by Type
Chronic Kidney Disease (CKD) Drugs
End-Stage Kidney Disease (ESRD) Drugs
Segment by Application
Hospitals
Specialty Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Renal Diseases Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Kidney disease commonly referred to as kidney disease or kidney disease, mainly manifested as abnormal urine volume, urination abnormalities, lumbago.Kidney disease drugs include blood pressure drugs, anti-hyperlipidemia drugs, erythropoietics (ESA), diuretics and so on.
The global Renal Diseases Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Renal Diseases Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Renal Diseases Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Renal Diseases Drug in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Renal Diseases Drug include Pfizer, Amgen, Roche, GlaxoSmithKline (GSK), Allergan, AbbVie, Kissei Pharmaceutical, AstraZeneca and FibroGen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Renal Diseases Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Renal Diseases Drug.
Report Scope
The Renal Diseases Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Renal Diseases Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Renal Diseases Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Amgen
Roche
GlaxoSmithKline (GSK)
Allergan
AbbVie
Kissei Pharmaceutical
AstraZeneca
FibroGen
Sanofi
Teva Pharmaceutical Industries
Johnson & Johnson
Keryx Biopharmaceuticals
Segment by Type
Chronic Kidney Disease (CKD) Drugs
End-Stage Kidney Disease (ESRD) Drugs
Segment by Application
Hospitals
Specialty Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Renal Diseases Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Renal Diseases Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chronic Kidney Disease (CKD) Drugs
1.2.3 End-Stage Kidney Disease (ESRD) Drugs
1.3 Market by Application
1.3.1 Global Renal Diseases Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Renal Diseases Drug Market Perspective (2019-2030)
2.2 Renal Diseases Drug Growth Trends by Region
2.2.1 Global Renal Diseases Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Renal Diseases Drug Historic Market Size by Region (2019-2024)
2.2.3 Renal Diseases Drug Forecasted Market Size by Region (2025-2030)
2.3 Renal Diseases Drug Market Dynamics
2.3.1 Renal Diseases Drug Industry Trends
2.3.2 Renal Diseases Drug Market Drivers
2.3.3 Renal Diseases Drug Market Challenges
2.3.4 Renal Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Renal Diseases Drug Players by Revenue
3.1.1 Global Top Renal Diseases Drug Players by Revenue (2019-2024)
3.1.2 Global Renal Diseases Drug Revenue Market Share by Players (2019-2024)
3.2 Global Renal Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Renal Diseases Drug Revenue
3.4 Global Renal Diseases Drug Market Concentration Ratio
3.4.1 Global Renal Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Renal Diseases Drug Revenue in 2023
3.5 Renal Diseases Drug Key Players Head office and Area Served
3.6 Key Players Renal Diseases Drug Product Solution and Service
3.7 Date of Enter into Renal Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Renal Diseases Drug Breakdown Data by Type
4.1 Global Renal Diseases Drug Historic Market Size by Type (2019-2024)
4.2 Global Renal Diseases Drug Forecasted Market Size by Type (2025-2030)
5 Renal Diseases Drug Breakdown Data by Application
5.1 Global Renal Diseases Drug Historic Market Size by Application (2019-2024)
5.2 Global Renal Diseases Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Renal Diseases Drug Market Size (2019-2030)
6.2 North America Renal Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Renal Diseases Drug Market Size by Country (2019-2024)
6.4 North America Renal Diseases Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Renal Diseases Drug Market Size (2019-2030)
7.2 Europe Renal Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Renal Diseases Drug Market Size by Country (2019-2024)
7.4 Europe Renal Diseases Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Renal Diseases Drug Market Size (2019-2030)
8.2 Asia-Pacific Renal Diseases Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Renal Diseases Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Renal Diseases Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Renal Diseases Drug Market Size (2019-2030)
9.2 Latin America Renal Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Renal Diseases Drug Market Size by Country (2019-2024)
9.4 Latin America Renal Diseases Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Renal Diseases Drug Market Size (2019-2030)
10.2 Middle East & Africa Renal Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Renal Diseases Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Renal Diseases Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Renal Diseases Drug Introduction
11.1.4 Pfizer Revenue in Renal Diseases Drug Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Renal Diseases Drug Introduction
11.2.4 Amgen Revenue in Renal Diseases Drug Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Renal Diseases Drug Introduction
11.3.4 Roche Revenue in Renal Diseases Drug Business (2019-2024)
11.3.5 Roche Recent Development
11.4 GlaxoSmithKline (GSK)
11.4.1 GlaxoSmithKline (GSK) Company Detail
11.4.2 GlaxoSmithKline (GSK) Business Overview
11.4.3 GlaxoSmithKline (GSK) Renal Diseases Drug Introduction
11.4.4 GlaxoSmithKline (GSK) Revenue in Renal Diseases Drug Business (2019-2024)
11.4.5 GlaxoSmithKline (GSK) Recent Development
11.5 Allergan
11.5.1 Allergan Company Detail
11.5.2 Allergan Business Overview
11.5.3 Allergan Renal Diseases Drug Introduction
11.5.4 Allergan Revenue in Renal Diseases Drug Business (2019-2024)
11.5.5 Allergan Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Renal Diseases Drug Introduction
11.6.4 AbbVie Revenue in Renal Diseases Drug Business (2019-2024)
11.6.5 AbbVie Recent Development
11.7 Kissei Pharmaceutical
11.7.1 Kissei Pharmaceutical Company Detail
11.7.2 Kissei Pharmaceutical Business Overview
11.7.3 Kissei Pharmaceutical Renal Diseases Drug Introduction
11.7.4 Kissei Pharmaceutical Revenue in Renal Diseases Drug Business (2019-2024)
11.7.5 Kissei Pharmaceutical Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Renal Diseases Drug Introduction
11.8.4 AstraZeneca Revenue in Renal Diseases Drug Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 FibroGen
11.9.1 FibroGen Company Detail
11.9.2 FibroGen Business Overview
11.9.3 FibroGen Renal Diseases Drug Introduction
11.9.4 FibroGen Revenue in Renal Diseases Drug Business (2019-2024)
11.9.5 FibroGen Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Renal Diseases Drug Introduction
11.10.4 Sanofi Revenue in Renal Diseases Drug Business (2019-2024)
11.10.5 Sanofi Recent Development
11.11 Teva Pharmaceutical Industries
11.11.1 Teva Pharmaceutical Industries Company Detail
11.11.2 Teva Pharmaceutical Industries Business Overview
11.11.3 Teva Pharmaceutical Industries Renal Diseases Drug Introduction
11.11.4 Teva Pharmaceutical Industries Revenue in Renal Diseases Drug Business (2019-2024)
11.11.5 Teva Pharmaceutical Industries Recent Development
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Company Detail
11.12.2 Johnson & Johnson Business Overview
11.12.3 Johnson & Johnson Renal Diseases Drug Introduction
11.12.4 Johnson & Johnson Revenue in Renal Diseases Drug Business (2019-2024)
11.12.5 Johnson & Johnson Recent Development
11.13 Keryx Biopharmaceuticals
11.13.1 Keryx Biopharmaceuticals Company Detail
11.13.2 Keryx Biopharmaceuticals Business Overview
11.13.3 Keryx Biopharmaceuticals Renal Diseases Drug Introduction
11.13.4 Keryx Biopharmaceuticals Revenue in Renal Diseases Drug Business (2019-2024)
11.13.5 Keryx Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
